Vaccines Europe

EU Member States are preparing to present their medium-term fiscal structural plans for the next 4-7 years to the European Commission by 20th September, and there is a critical window of opportunity to prioritise investment in health prevention, including immunisation. This new report by The European House-Ambrosetti, supported by IFPMA and Vaccines Europe, calls for a shift towards prevention-based healthcare to secure economic stability for EU health systems. The economic value of prevention has been well documented. For example, adult immunisation programmes return up to 19 times their initial investment. Despite this, most Member States dedicate only 0.5% of their healthcare budgets to prevention. We need an urgent change in direction - embedding preventative healthcare such as immunisation into EU Member States’ fiscal policies is paramount to ensure the economic sustainability of healthcare, social care, and welfare systems. https://bit.ly/4gpqWVw

The recognition of vaccine specificities in the EU #HTA Regulation is a good first step towards streamlining the way vaccines are assessed in the EU. We now need to ensure that these specificities are implemented appropriately in the HTA framework https://bit.ly/49gcOuw #WeWontRest

A favourable regulatory environment and prioritising investment in prevention would be key to reverse the worrying decline in immunisation clinical trials in EU. Where innovation happens matters: how can we ensure Europeans benefit from the latest advances in medicine? https://bit.ly/3C30XTM #WeWontRest #RebootLifeSciences

The EU #HTA Regulation is almost here: as of 2025, joint scientific consultations will be available for vaccines too. Now is the time to ensure its framework is appropriate for vaccines https://bit.ly/49gcOuw #WeWontRest

🌍 EUVABECO’s Active Role in Key EU Health Events 🌍 EUVABECO recently showcased its efforts to enhance vaccination practices across Europe at two events in Lisbon. Learn more about these sessions on our website: 1️⃣ Scientific Session at the European Public Health Conference: https://lnkd.in/dG34Eanb 2️⃣ Pre-Conference on Best Practices in EU Health Policies: https://lnkd.in/dZvCMMQN Through these events, EUVABECO continues to foster collaborations and share valuable insights to improve the immunisation process across the EU. European Health and Digital Executive Agency (HaDEA), EUPHA - European Public Health Association, Global Health Section EUPHA, University of Crete, Rīga Stradiņš University, Sciensano, Vaccines Europe, SYADEM Christos Lionis, Elena Petelos, Georgios Margetidis, Francois Kaag, Matthieu Billuart, Dace Zavadska, Sibilia Quilici Ministério da Saúde de Portugal, Universität des Saarlandes, Uniwersytet Jagielloński (Jagiellonian University), University of Thessaly Laboratory of Hygiene and Epidemiology, Wroclaw Medical University, Agence eSanté Luxembourg, FRATEM ASBL, @Cimbiose #EUVABECO #Vaccination #PublicHealth #EUHealth #HealthInnovation #Collaboration

Immunisation is one of the most cost-effective health prevention tools, saving millions of lives every year and bringing significant return on investment. And yet, only 0.5% of healthcare budgets in most EU countries are dedicated to it. We urgently need a paradigm shift towards prevention-based healthcare #PreventionForChange https://bit.ly/3YNvdLq 

In 2019, nearly 5 million deaths were associated with bacterial #AMR worldwide, with this number projected to rise to 10 million deaths per year globally by 2050. This is a challenge that cannot be solved by one actor alone but must be confronted using every available tool, including vaccination. An attractive innovation ecosystem in the EU is required that encourages the uptake of existing vaccines and supports the development of next generation vaccines that address AMR #WAAW #EAAD https://bit.ly/3CmUH9N

Last week Vaccines Europe was pleased to welcome IFPMA vaccines CEO's jointly with Vaccines Europe Board in Brussels for a fruitful and timely discussion and engagement on how Europe can regain its leadership in vaccine development and manufacturing.   The presence of the senior leadership of the vaccine industry in #Brussels right at the beginning of a new legislative mandate is a profound testimony of the vaccine industry willingness to contribute to the competitiveness of Europe and to collaborate with all stakeholders to deliver on the potential of the innovative vaccine industry to contribute to the resiliency of the EU healthcare systems, societies and economies.   If we want to collectively protect people against evolving health challenges, we need an European environment that foster innovation and value recognition of life course immunisation in Europe.   My key takeaways from the engaging discussions: 👉 Uptake : Increasing vaccination coverage rates for people from all ages is key to ensure Europeans are protected from vaccine-preventable diseases. We need to work together across the entire vaccine ecosystem to continue efforts to increase uptake across the continent. 👉 Investment: We need to build on the unique socio-economic value of immunisation - adult immunisation programmes return up to 19 times their initial investment. Prioritising investment in prevention is crucial, and we need a paradigm shift towards prevention-based healthcare models. The #NewEconomicGovernanceFramework represent an unique opportunity for the EU member states to invest in their health systems, towards more prevention. 👉 Incentives: Vaccine innovation can help address the healthcare challenges of today and tomorrow, such as #AMR, #climatechange and the #ageing population. There are over 100 vaccines in the pipeline of Vaccines Europe member companies, and it is essential to support this innovation and foster an environment that incentivises vaccine R&D and manufacturing. #VaccinesSaveLife #VaccinesSaveMoney #WeWontRest #PreventionforChange

The EU share of immunisation clinical trials has fallen from 17% in 2018 to just 8% in 2023. In the meantime, more and more vaccine clinical trials are conducted in Asia. How can we close the gap and ensure people living in Europe don’t miss out on the opportunity to access the latest vaccines? Read more: https://bit.ly/3C30XTM #WeWontRest #RebootLifeSciences 

Let’s dive into Chapter 1 of our Consensus Report: Data and evidence for decision-making! 📊 Data and evidence are the backbone of effective vaccination strategies – they inform and guide decision-making on new vaccines and vaccination programs, support the surveillance of vaccine-preventable diseases (VPDs), and monitor vaccination coverage and confidence. Yet, critical gaps remain that hinder progress, including: ➡ Lack of nationwide data on complications linked to several infections in population subgroups, as well as on vaccination coverage rates (VCRs). ➡ Fragmented national approaches to the evaluation of vaccines/vaccination programmes, leading to diverging levels of health protection across European countries. Our recommended actions: 🔍 Enhance data collection and evidence generation to support the strengthening of vaccination policies, strategies, and the broader health care system. 💡 Strengthen the alignment of national approaches to evidence-based decision-making on vaccination through a common European value framework: Let’s harness the power of data to drive impactful vaccination policies and strengthen programs across Europe! 🌍 Stay tuned for Chapter 2, where we explore our recommendations on vaccine beliefs, perceptions and confidence! Read more 👉 https://lnkd.in/ehVPf-px